PMID: 11927674Apr 3, 2002Paper

Dopamine selectively reduces GABA(B) transmission onto dopaminergic neurones by an unconventional presynaptic action

The Journal of Physiology
Mauro FedericiNicola B Mercuri

Abstract

The functioning of midbrain dopaminergic neurones is closely involved in mental processes and movement. In particular the modulation of the inhibitory inputs on these cells might be crucial in controlling firing activity and dopamine (DA) release in the brain. Here, we report a concentration-dependent depressant action of dopamine on the GABA(B) IPSPs intracellularly recorded from dopaminergic neurones. Such effect was observed in spite of the presence of D(1)/D(2) dopamine receptor antagonists. A reduction of the GABA(B) IPSPs was also caused by noradrenaline (norepinephrine) and by L-beta-3,4-dihydroxyphenylalanine (L-DOPA), which is metabolically transformed into DA. The DA-induced depression of the IPSPs was partially antagonised by the alpha2 antagonists yohimbine and phentolamine. DA did not change the postsynaptic effects of the GABA(B) agonist baclofen, suggesting a presynaptic site of action. Furthermore, DA did not modulate the GABA(A)-mediated IPSP. The DA-induced depression of the GABA(B) IPSP occluded the depression produced by serotonin and was not antagonized by serotonin antagonists. The DA- and 5-HT-induced depression of the GABA(B) IPSP persisted when calcium and potassium currents were reduced in to the presy...Continue Reading

References

May 1, 1992·The Journal of Physiology·S W Johnson, R A North
Jun 1, 1990·British Journal of Pharmacology·N B MercuriG Bernardi
Feb 12, 1981·Nature·A CheramyJ Glowinski
Mar 1, 1995·The European Journal of Neuroscience·N B MercuriG Bernardi
Nov 25, 1993·Nature·D L Cameron, J T Williams
Jan 1, 1995·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·G SedvallC Halldin
Jan 1, 1996·Annual Review of Neuroscience·F J White
Jan 1, 1997·Annual Review of Pharmacology and Toxicology·P J Conn, J P Pin
Sep 12, 1997·The Journal of Biological Chemistry·T M IshiiJ P Adelman
Aug 26, 1998·Neurology·T N ChaseP J Blanchet
Apr 3, 1999·Synapse·L Matuszewich, B K Yamamoto
Mar 11, 2000·Journal of Neurophysiology·C D Fiorillo, J T Williams
Jul 8, 2000·Proceedings of the National Academy of Sciences of the United States of America·A Abi-DarghamM Laruelle
Feb 27, 2001·Nature Neuroscience·C A PaladiniJ T Williams

❮ Previous
Next ❯

Citations

Jan 3, 2006·Brain Research·Adam C Munhall, Steven W Johnson
Jun 7, 2005·Trends in Pharmacological Sciences·Nicola Biagio Mercuri, Giorgio Bernardi
Dec 31, 2004·Movement Disorders : Official Journal of the Movement Disorder Society·Francisca Sueli MonteVeralice Meireles Sales de Bruin
Oct 9, 2007·Parkinsonism & Related Disorders·Peter RiedererHeinz Reichmann
May 7, 2004·The European Journal of Neuroscience·Kazuya SaitohKaoru Takakusaki
Mar 14, 2013·Experimental Neurology·Ezia GuatteoJanusz Lipski
Oct 20, 2010·The European Journal of Neuroscience·Jennifer C NaylorScott D Moore
Mar 28, 2019·Journal of Neurophysiology·Cecilia Bove, R Alberto Travagli
Dec 6, 2003·The European Journal of Neuroscience·Ke-Zhong ShenSteven W Johnson

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here